An enhanced 13-week bioassay

An alternative to the 2-year bioassay to screen for human carcinogenesis

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The 2-year rodent bioassay has become the standard carcinogenicity screen for chemicals, despite concerns of costs, time, and excessive doses. More importantly, there are increasing concerns regarding its relevance to human carcinogenic risk, especially for non-DNA reactive chemicals. Cancer risk can be increased either by direct damage to DNA (DNA reactivity) or by increased cell proliferation. Utilizing the scientific basis for mode of action analysis in the framework that has been developed for extrapolating to human relevance, a short-term screen is proposed as a replacement for the 2-year bioassay. Chemicals are evaluated for DNA reactivity, immunosuppression, and estrogenic activity, known mechanisms of human carcinogenesis, by in vitro and/or in vivo tests. The chemical can then be evaluated for toxicity and/or increased cell proliferation in target tissues. This relies primarily on evaluation of organ weights and histopathology, and also utilizes data from blood and urine chemistries and DNA-labeling indices. Significant concern is raised regarding the relevance of evaluation of tissues that are present in rats or mice but not humans, and the relevance of proliferative responses in rodent endocrine tissues. In developing alternative procedures to evaluate chemicals for possible carcinogenic activity in humans, it is important not to rely on the 2-year rodent bioassay for validation of the new procedure. It is time to discontinue the performance of the 2-year rodent bioassay.

Original languageEnglish (US)
Pages (from-to)497-502
Number of pages6
JournalExperimental and Toxicologic Pathology
Volume62
Issue number5
DOIs
StatePublished - Sep 1 2010

Fingerprint

Bioassay
Biological Assay
Rodentia
Carcinogenesis
DNA
Cell proliferation
Tissue
Cell Proliferation
Organ Size
Human Activities
Immunosuppression
DNA Damage
Labeling
Urine
Toxicity
Rats
Costs and Cost Analysis
Blood
Neoplasms
Costs

Keywords

  • Carcinogenesis testing
  • Cell proliferation
  • Estrogenic activity
  • Genotoxicity
  • Human relevance framework
  • Immunosuppression
  • Risk assessment

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Cell Biology

Cite this

An enhanced 13-week bioassay : An alternative to the 2-year bioassay to screen for human carcinogenesis. / Cohen, Samuel Monroe.

In: Experimental and Toxicologic Pathology, Vol. 62, No. 5, 01.09.2010, p. 497-502.

Research output: Contribution to journalReview article

@article{6b40cd61ecd447d28bd5c8bf99ed4825,
title = "An enhanced 13-week bioassay: An alternative to the 2-year bioassay to screen for human carcinogenesis",
abstract = "The 2-year rodent bioassay has become the standard carcinogenicity screen for chemicals, despite concerns of costs, time, and excessive doses. More importantly, there are increasing concerns regarding its relevance to human carcinogenic risk, especially for non-DNA reactive chemicals. Cancer risk can be increased either by direct damage to DNA (DNA reactivity) or by increased cell proliferation. Utilizing the scientific basis for mode of action analysis in the framework that has been developed for extrapolating to human relevance, a short-term screen is proposed as a replacement for the 2-year bioassay. Chemicals are evaluated for DNA reactivity, immunosuppression, and estrogenic activity, known mechanisms of human carcinogenesis, by in vitro and/or in vivo tests. The chemical can then be evaluated for toxicity and/or increased cell proliferation in target tissues. This relies primarily on evaluation of organ weights and histopathology, and also utilizes data from blood and urine chemistries and DNA-labeling indices. Significant concern is raised regarding the relevance of evaluation of tissues that are present in rats or mice but not humans, and the relevance of proliferative responses in rodent endocrine tissues. In developing alternative procedures to evaluate chemicals for possible carcinogenic activity in humans, it is important not to rely on the 2-year rodent bioassay for validation of the new procedure. It is time to discontinue the performance of the 2-year rodent bioassay.",
keywords = "Carcinogenesis testing, Cell proliferation, Estrogenic activity, Genotoxicity, Human relevance framework, Immunosuppression, Risk assessment",
author = "Cohen, {Samuel Monroe}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.etp.2009.06.011",
language = "English (US)",
volume = "62",
pages = "497--502",
journal = "Experimental and Toxicologic Pathology",
issn = "0940-2993",
publisher = "Urban und Fischer Verlag Jena",
number = "5",

}

TY - JOUR

T1 - An enhanced 13-week bioassay

T2 - An alternative to the 2-year bioassay to screen for human carcinogenesis

AU - Cohen, Samuel Monroe

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The 2-year rodent bioassay has become the standard carcinogenicity screen for chemicals, despite concerns of costs, time, and excessive doses. More importantly, there are increasing concerns regarding its relevance to human carcinogenic risk, especially for non-DNA reactive chemicals. Cancer risk can be increased either by direct damage to DNA (DNA reactivity) or by increased cell proliferation. Utilizing the scientific basis for mode of action analysis in the framework that has been developed for extrapolating to human relevance, a short-term screen is proposed as a replacement for the 2-year bioassay. Chemicals are evaluated for DNA reactivity, immunosuppression, and estrogenic activity, known mechanisms of human carcinogenesis, by in vitro and/or in vivo tests. The chemical can then be evaluated for toxicity and/or increased cell proliferation in target tissues. This relies primarily on evaluation of organ weights and histopathology, and also utilizes data from blood and urine chemistries and DNA-labeling indices. Significant concern is raised regarding the relevance of evaluation of tissues that are present in rats or mice but not humans, and the relevance of proliferative responses in rodent endocrine tissues. In developing alternative procedures to evaluate chemicals for possible carcinogenic activity in humans, it is important not to rely on the 2-year rodent bioassay for validation of the new procedure. It is time to discontinue the performance of the 2-year rodent bioassay.

AB - The 2-year rodent bioassay has become the standard carcinogenicity screen for chemicals, despite concerns of costs, time, and excessive doses. More importantly, there are increasing concerns regarding its relevance to human carcinogenic risk, especially for non-DNA reactive chemicals. Cancer risk can be increased either by direct damage to DNA (DNA reactivity) or by increased cell proliferation. Utilizing the scientific basis for mode of action analysis in the framework that has been developed for extrapolating to human relevance, a short-term screen is proposed as a replacement for the 2-year bioassay. Chemicals are evaluated for DNA reactivity, immunosuppression, and estrogenic activity, known mechanisms of human carcinogenesis, by in vitro and/or in vivo tests. The chemical can then be evaluated for toxicity and/or increased cell proliferation in target tissues. This relies primarily on evaluation of organ weights and histopathology, and also utilizes data from blood and urine chemistries and DNA-labeling indices. Significant concern is raised regarding the relevance of evaluation of tissues that are present in rats or mice but not humans, and the relevance of proliferative responses in rodent endocrine tissues. In developing alternative procedures to evaluate chemicals for possible carcinogenic activity in humans, it is important not to rely on the 2-year rodent bioassay for validation of the new procedure. It is time to discontinue the performance of the 2-year rodent bioassay.

KW - Carcinogenesis testing

KW - Cell proliferation

KW - Estrogenic activity

KW - Genotoxicity

KW - Human relevance framework

KW - Immunosuppression

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=77955514001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955514001&partnerID=8YFLogxK

U2 - 10.1016/j.etp.2009.06.011

DO - 10.1016/j.etp.2009.06.011

M3 - Review article

VL - 62

SP - 497

EP - 502

JO - Experimental and Toxicologic Pathology

JF - Experimental and Toxicologic Pathology

SN - 0940-2993

IS - 5

ER -